Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.61 |
| ▸ | BCHE | P06276 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 8/20 | 0.52 |
| ▸ | NAAA | Q02083 | 2/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22134964 | 0.96 | EPHX1 (0.66) | GAAEPHX1BCHEACHENAAA | |
| SCHEMBL22136179 | 0.95 | EPHX1 (0.69) | GAAEPHX1BCHEACHENAAA | |
| SCHEMBL2801495 | 0.95 | EPHX1 (0.69) | GAAEPHX1BCHEACHENAAA | |
| SCHEMBL16374741 | 0.91 | EPHX1 (0.64) | GAAEPHX1BCHENAAA | |
| SCHEMBL12991745 | 0.90 | EPHX1 (0.67) | GAAEPHX1BCHENAAA | |
| SCHEMBL14703637 | 0.90 | EPHX1 (0.62) | GAAEPHX1NAAA | |
| SCHEMBL20928290 | 0.89 | EPHX1 (0.65) | GAAEPHX1BCHENAAAKCNA3 | |
| SCHEMBL21059247 | 0.88 | EPHX1 (0.65) | GAAEPHX1NAAA | |
| SCHEMBL15975473 | 0.88 | EPHX1 (0.65) | GAAEPHX1NAAA | |
| SCHEMBL24263885 | 0.88 | GAA (0.58) | GAAEPHX1BCHEACHENAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022125904-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125915-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125908-A1 | ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125884-A1 | IMMUNOCONJUGATES COMPRISING AN ANTI-CEA ANTIBODY LINKED BY CONJUGATION TO ONE OR|MORE 8-HET-2- AMINOBENZAZEPINE DERIVATIVES USEFUL IN TREATING CANCER | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125891-A2 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-102264710-B | Cysteine protease inhibitors | MEDIVIR UK LTD | 2014-11-05 | — | — | CN | disclosed |
| US-20040229818-A1 | Hepatitis C inhibitor compound | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229818-A1 | Hepatitis C inhibitor compound | HAVCR2, GTF3C1, RNASE1 | GAA 1146/4885EPHX1 1187/4885BCHE 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.